Dr. Ben Bikman: How To Reverse Insulin Resistance Through Diet, Exercise, & Sleep

Bikman emphasizes that breakfast, worldwide, has become dessert—pure sugar and starch. After an overnight fast, insulin is low; spiking it with a high-carb meal immediately switches off fat burning and reinforces insulin resistance. He suggests either just drinking yerba mate, coffee, or tea (with optional butter, which he doesn’t consider breaking a fast because of the endocrine definition) or eating a meal of eggs, meat, or fish with vegetables and berries. He notes that this single change can, within 90 days, normalize HbA1c in type 2 diabetics (as shown in his published case series) and is the most impactful daily lever. He practices this himself: he doesn’t eat breakfast, drinks yerba mate, and has his main meal at lunch. This approach also keeps insulin low long enough to shift the body into fat-burning mode, enhancing metabolic flexibility.

Bikman views exercise as the second lever after diet. He argues that because 80% of post-meal glucose disposal goes into muscle, having more muscle creates a large metabolic buffer. Strength training builds that buffer and improves insulin sensitivity even when time is limited (30-min strength sessions outperform aerobic for insulin sensitivity). He stresses going to failure, whether with heavy weight/low rep or light weight/high rep. The exercise snack concept: a 10-15 minute walk or bodyweight squats after the biggest meal cuts the glucose spike by half or more, likely by activating AMPK and GLUT4 translocation independent of insulin. He shares that even walking around his building after lunch achieves this. He also notes that high-intensity interval training is powerful but shouldn’t replace strength work.

Bikman acknowledges that clinical trials show eating only breakfast and lunch yields better metabolic outcomes than lunch and dinner, but he personally eats dinner for family reasons. His compromise is a big lunch and a lighter dinner, with no snacking afterward. He explains that evening snacking is the weakest moment for most people, and giving in creates a vicious cycle: the sugar spike causes a reactive hypoglycemia at bedtime, activating the sympathetic nervous system—heart pounding, feeling hot, anxiety—mimicking insomnia. The high insulin also suppresses melatonin and fat burning overnight. He advises stopping eating 3-4 hours before bed and, if cravings strike, using bitter tastes (like apple cider vinegar) to reduce sweet cravings.

Bikman calls it an ‘absolute travesty’ that insulin is not standard on metabolic panels. He sets target fasting insulin ≤6 μU/mL; 7–15 is borderline; above 20 is a clear problem. He also highlights the triglyceride/HDL ratio: <1.5 is good, and studies show it accurately reflects the shift from large buoyant (pattern A) to small dense (pattern B) LDL particles. Uric acid is another longevity predictor from the Amoris study. These markers provide a practical, accessible way to assess metabolic health without relying on glucose alone.

Bikman’s three-part dietary advice for his clinical study: 1) Control carbs: eat whole fruits and vegetables, avoiding the most sugary and starchy ones; 2) Prioritize protein; 3) Don’t fear the fat that comes with that protein. He stresses that in nature all protein comes with fat, and consuming them together improves protein digestion via bile and enhances muscle protein synthesis. This approach naturally eliminates processed foods because if you’re eating whole foods, you automatically ditch the bags and boxes with barcodes that combine refined starches/sugars and seed oils. He acknowledges calories matter but insists that lowering insulin via carb control is the first step because it enables the metabolic advantages of higher basal metabolic rate and ketone calorie wasting, making calorie reduction easier later without disabling hunger.

Bikman’s unconventional protocol stems from a 1996 study showing that obese individuals completely lack a GLP-1 response to a high-carb meal, whereas lean individuals have a robust surge that produces satiety. He argues that low-dose GLP-1 agonism corrects this deficit, enabling the person to feel satisfied with fewer carbs. The goal is not weight loss per se but to create a 90-day window where they can practice new habits without the constant drive to eat. He describes an ideal clinical conversation: ‘You need to control carbs’ / ‘I can’t, I’m addicted’ / ‘Let’s use a low dose to help you control cravings.’ After 90 days, the drug is stopped to see if habits have stuck. He knows people who succeeded with this approach. He strongly warns against the current high-dose, indefinite model, citing his own unpublished data showing muscle catabolism at plasma-level doses, plus elevated risks of major depression (3×), suicidal behavior (2×), and blindness (2×) from recent reports.

Bikman argues that insulin resistance is a state where insulin concentrations climb 2- to 4-fold while glucose remains within the normal range. The glucocentric paradigm means clinicians miss the earliest sign—insulin itself. He calls insulin ‘the metabolic canary in the coal mine’ and says that if insulin were routinely measured, treatment could begin when the problem is still easily reversible. He ties this to skin signs (acanthosis nigricans, skin tags) that are visible windows into insulin resistance, and notes that even dynamic CGM readings (glucose failing to return to baseline by 2 hours after a carbohydrate load) are more informative than fasting glucose. This shift would also prevent the harmful practice of prescribing additional insulin to type 2 diabetics, which pushes already high insulin to super-physiological levels and accelerates mortality from hyperinsulinemia and insulin resistance.

Bikman decided the one message of his career would be that to some degree most chronic disease traces back to insulin resistance. He elaborates using cancer (breast/prostate), Alzheimer’s, PCOS, erectile dysfunction, fatty liver, and hypertension. Insulin resistance creates a unique pathology: some cells suffer from impaired insulin signaling (e.g., endothelial cells producing less nitric oxide, causing erectile dysfunction), while other cells are overstimulated by the compensatory high insulin (e.g., ovaries over-inhibiting aromatase, leading to PCOS). He argues that if clinicians treated the ‘common soil’ instead of trimming branches, outcomes would simplify dramatically. This is not to say insulin is the sole cause, but it is always a major contributor.

Bikman distinguishes ‘fast’ from ‘slow’ insulin resistance. Fast IR can be triggered within hours by stress hormones (cortisol, epinephrine), inflammation (cytokines), or excess insulin itself—his own lab published on insulin causing its own resistance. If the stimulus is removed, IR resolves quickly. Slow IR builds over years and begins with fat cell hypertrophy: as fat cells swell, they become resistant to insulin’s anti-lipolytic signal, causing high free fatty acids and high insulin simultaneously. This state favors ceramide synthesis (especially from palmitate) over fat oxidation, and ceramides block the insulin signaling cascade at the AKT phosphorylation level. He notes that all three fast stimuli also induce ceramide production. Thus, ectopic fat toxicity is not about storage quantity but about the metabolic milieu that makes ceramides. The slow form settles in fat tissue first, then spreads to liver, muscle, and alpha cells.

Bikman explains GLP-1’s mechanism: at low doses it primarily inhibits glucagon (through alpha-cell action), helping correct blood glucose in type 2 diabetes; at high doses it delays gastric emptying and centrally suppresses appetite. He worries about effects of food sitting in the stomach for up to 20 hours, altering drug absorption, causing nausea, ‘Ozempic burps,’ and potentially reducing nutrient absorption. He cites the 1996 paper showing that lean individuals have a strong GLP-1 surge after a high-carb meal, while obese individuals show no significant response. He suggests that for obesity, the real issue is an absent off-switch for carbohydrates. Thus, low-dose GLP-1 agonists could specifically help someone feel satiated from fewer carbs, and by pairing the drug with coaching on habit change, the person can rewire their eating patterns. He cites people who, after a 90-day cycle, had lasting habit change. He also warns of high-dose risks: unpublished data from his lab shows muscle catabolism at current plasma-equivalent doses; recent reports link high-dose use to doubled risk of blindness, tripled major depression, and doubled suicidal behavior.

Bikman explains that acetic acid, the short-chain fatty acid in vinegar, punches above its weight metabolically. It inhibits hepatic gluconeogenesis (relevant in type 2 diabetes where glucagon is high) and stimulates AMPK, the energy-sensing kinase that triggers GLUT4 translocation to the muscle membrane—the same pathway exercise uses to pull glucose out of the blood without insulin. He notes that modern diets lack fermented foods, so we rarely get short-chain fatty acids. Taking 2 tablespoons before a starchy meal can visibly lower the glucose curve day-to-day. He also connects acetate to lactate, noting both may signal through similar mechanisms.